|
1
|
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.
|
AIDS
|
2005
|
1.66
|
|
2
|
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
|
Clin Infect Dis
|
2010
|
1.64
|
|
3
|
Switching HIV treatment in adults based on CD4 count versus viral load monitoring: a randomized, non-inferiority trial in Thailand.
|
PLoS Med
|
2013
|
1.20
|
|
4
|
Predictors of 5-year mortality in HIV-infected adults starting highly active antiretroviral therapy in Thailand.
|
J Acquir Immune Defic Syndr
|
2012
|
1.18
|
|
5
|
Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.
|
J Antimicrob Chemother
|
2009
|
1.14
|
|
6
|
A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
|
Pediatr Infect Dis J
|
2010
|
1.05
|
|
7
|
Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
|
Antivir Ther
|
2009
|
1.02
|
|
8
|
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
|
Antivir Ther
|
2011
|
1.02
|
|
9
|
Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.
|
Antimicrob Agents Chemother
|
2012
|
0.95
|
|
10
|
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
|
Clin Infect Dis
|
2011
|
0.93
|
|
11
|
Raltegravir pharmacokinetics during pregnancy.
|
J Acquir Immune Defic Syndr
|
2014
|
0.92
|
|
12
|
Intensive pharmacokinetics of zidovudine 200 mg twice daily in HIV-1-infected patients weighing less than 60 kg on highly active antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2006
|
0.92
|
|
13
|
Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.
|
Pharmacogenomics
|
2012
|
0.90
|
|
14
|
Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
|
Br J Clin Pharmacol
|
2012
|
0.89
|
|
15
|
Pharmacokinetic optimization of antiretroviral therapy in pregnancy.
|
Clin Pharmacokinet
|
2012
|
0.86
|
|
16
|
Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
|
Pediatr Infect Dis J
|
2015
|
0.83
|
|
17
|
Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
|
J Acquir Immune Defic Syndr
|
2013
|
0.82
|
|
18
|
Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir.
|
J Antimicrob Chemother
|
2012
|
0.81
|
|
19
|
Does pregnancy affect the pharmacokinetics of efavirenz?
|
AIDS
|
2014
|
0.80
|
|
20
|
No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.
|
J Acquir Immune Defic Syndr
|
2015
|
0.80
|
|
21
|
Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.
|
AIDS
|
2015
|
0.78
|
|
22
|
Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.
|
Pediatr Infect Dis J
|
2014
|
0.78
|
|
23
|
Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.
|
Pediatr Infect Dis J
|
2012
|
0.78
|
|
24
|
Pharmacological assessment of efavirenz weight-band dosing recommendations in HIV-infected Thai children.
|
J Acquir Immune Defic Syndr
|
2013
|
0.78
|
|
25
|
Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children.
|
Pediatr Infect Dis J
|
2007
|
0.78
|
|
26
|
The role of formulation on the pharmacokinetics of antiretroviral drugs.
|
Expert Opin Drug Metab Toxicol
|
2014
|
0.78
|
|
27
|
Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.
|
J Acquir Immune Defic Syndr
|
2015
|
0.78
|
|
28
|
New-Onset Diabetes and Antiretroviral Treatments in HIV-Infected Adults in Thailand.
|
J Acquir Immune Defic Syndr
|
2015
|
0.78
|
|
29
|
Efavirenz Concentrations and Probability of HIV Replication in Children.
|
Pediatr Infect Dis J
|
2015
|
0.78
|
|
30
|
Developmental pharmacokinetic changes of Lamivudine in infants and children.
|
J Clin Pharmacol
|
2011
|
0.76
|
|
31
|
Correction: Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV.
|
PLoS One
|
2015
|
0.75
|
|
32
|
Correction: Modeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV.
|
PLoS One
|
2015
|
0.75
|
|
33
|
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.
|
Pediatr Infect Dis J
|
2016
|
0.75
|
|
34
|
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
35
|
Pharmacogenomics and the prevention of mother-to-child transmission of HIV.
|
Pharmacogenomics
|
2010
|
0.75
|
|
36
|
Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.
|
Antivir Ther
|
2015
|
0.75
|
|
37
|
A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines.
|
Pediatr Infect Dis J
|
2017
|
0.75
|